AIM2 exhibited both growth inhibitory effects in colon, hepatoma, nasopharyngeal, and lung cancers, and proliferation-promoting effects in cutaneous squamous cell carcinomas (SCCs) and endometrial cancers (57–60). This evidence concerns the gene AIM2 and endometrial cancer.